134: Marked variability in the access to curative radiotherapy for NSCLC in the UK.

MLA

McAleese, J., et al. “134: Marked Variability in the Access to Curative Radiotherapy for NSCLC in the UK.” Lung Cancer (01695002), vol. 103, Jan. 2017, pp. S60–61. EBSCOhost, https://doi.org/10.1016/S0169-5002(17)30184-8.

APA

McAleese, J., Baluch, S., & Drinkwater, K. (2017). 134: Marked variability in the access to curative radiotherapy for NSCLC in the UK. Lung Cancer (01695002), 103, S60–S61. https://doi.org/10.1016/S0169-5002(17)30184-8

Chicago

McAleese, J., S. Baluch, and K. Drinkwater. 2017. “134: Marked Variability in the Access to Curative Radiotherapy for NSCLC in the UK.” Lung Cancer (01695002) 103 (January): S60–61. doi:10.1016/S0169-5002(17)30184-8.